



Bibliography of Medication Compliance

**costs of medication noncompliance
publications sorted by therapeutic areas**

Table of Contents

Peer-reviewed papers..... 3

Review articles 6

Books 9

Book chapters 9

Abstracts from conference/symposium/workshop 10

Newsletters, editorials, commentaries, special reports..... 13

Websites 13

Others 13

Contact us 14

Peer-reviewed papers

1. Arthritis/osteoporosis/musculoskeletal disorders

Jonsson B, Haglund U. Cost-effectiveness of misoprostol in Sweden. *Int J Tech Assess Health Care* 1992;8:234-44

2. Cancer

No articles identified.

3. Cardiovascular diseases/disorders (including smoking, obesity & stroke)

Basskin L. How to determine the extent and costs of noncompliance with drug therapy. *Formulary*. 1998 Feb;33(2):139-144.

McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a Medicaid population. *Medical Care* 1994;32:214-26

Neal WW. Reducing costs and improving compliance. *Am J Cardiol*. 1989 Jan 17;63(4):17B-20B.

Paramore LC, Halpern MT, Lapuerta P, Hurley JS, Frost FJ, Fairchild DG, Bates D. Impact of poorly controlled hypertension on healthcare resource utilization and cost. *Am J Manag Care*. 2001 Apr;7(4):389-98.

Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. *Clin Ther*. 1997 Nov-Dec;19(6):1446-57; discussion 1424-5.

Sclar DA, Chin A, Skaer TL, Okamoto MP, Nakahiro RK, Gill MA. Effect of health education in promoting prescription refill compliance among patients with hypertension. *Clin Ther*. 1991 Jul-Aug;13(4):489-95.

Sclar DA, Skaer TL, Robison LM, Chin A, Okamoto MP, Nakahiro RK, Gill MA. Effect of antihypertensive formulation on health service expenditures. *Clin Auton Res*. 1993 Dec;3(6):363-8.

4. Diabetes/metabolic disorder

Clark WF, Churchill DN, Forwell L, Macdonald G, Foster S. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy. *CMAJ* 2000;162: 195-198

5. Eye & skin diseases/disorders

No articles identified.

6. Infection

Burman WJ, Dalton CB, Cohn DL, Butler JR, Reves RR. A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis. *Chest*. 1997 Jul;112(1):63-70.

Desvarieux M, Hyppolite PR, Johnson WD Jr, Pape JW. A novel approach to directly observed therapy for tuberculosis in an HIV-endemic area. *Am J Public Health*. 2001 Jan;91(1):138-41.

Gourevitch MN, Alcabes P, Wasserman WC, Arno PS. Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis. *Int J Tuberc Lung Dis*. 1998 Jul;2(7):531-40.

Palmer CS, Miller B, Halpern MT, Geiter LJ. A model of the cost-effectiveness of directly observed therapy for treatment of tuberculosis. *J Public Health Manag Pract*. 1998 May;4(3):1-13.

Scharfstein JA, Paltiel AD, Weinstein MC, Seage GR, Losina E, Craven DE, Freedberg KA. The cost-effectiveness of prophylaxis for *Mycobacterium avium* complex in AIDS. *Int J Technol Assess Health Care*. 1999 Summer;15(3):531-47.

Snyder DC, Chin DP. Cost-effectiveness analysis of directly observed therapy for patients with tuberculosis at low risk for treatment default. *Am J Respir Crit Care Med*. 1999 Aug;160(2):582-6.

Weis SE, Foresman B, Matty KJ, Brown A, Blais FX, Burgess G, King B, Cook PE, Slocum PC. Treatment costs of directly observed therapy and traditional therapy for *Mycobacterium tuberculosis*: a comparative analysis. *Int J Tuberc Lung Dis*. 1999 Nov;3(11):976-84.

7. Gastrointestinal diseases/disorders

No articles identified.

8. Mental health

Medical costs high for depression patients who resist treatment. [No authors listed] *Capitation Rates Data*. 2001 Sep;6(9):101-3.

Durrenberger S, Rogers T, Walker R, de Leon J. Economic grand rounds: the high costs of care for four patients with mania who were not compliant with treatment. *Psychiatr Serv*. 1999 Dec;50(12):1539-42.

Kasper JA, Hoge SK, Feucht-Haviar T, Cortina J, Cohen B. Prospective study of patients' refusal of antipsychotic medication under a physician discretion review procedure. *Am J Psychiatry*. 1997 Apr;154(4):483-9.

Li J, McCombs JS, Stimmel GL. Cost of treating bipolar disorder in the California Medicaid (Medi-Cal) program. *J Affect Disord.* 2002 Sep;71(1-3):131-9.

Revicki DA, Brown RE, Palmer W, Bakish D, Rosser WW, Anton SF, Feeny D. Modelling the cost effectiveness of antidepressant treatment in primary care. *Pharmacoeconomics.* 1995 Dec;8(6):524-40.

Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. *Psychiatr Serv.* 2001 Jun;52(6):805-11.

Weiden PJ, Olfson M. Cost of relapse in schizophrenia. *Schizophrenia Bulletin* 1995; 21(3): 419-29.

9. Neurological diseases/disorders & pain

No articles identified.

10. Other diseases/disorders – **includes articles of all conditions/multiple conditions/general health**

Billups SJ, Malone DC, Carter BL. The relationship between drug therapy noncompliance and patient characteristics, health-related quality of life, and health care costs. *Pharmacotherapy.* 2000 Aug;20(8):941-9.

Burgess MM. Ethical and economic aspects of noncompliance and overtreatment. *Can Med Assoc J.* 1989 Oct 15;141(8):777-80.

Cleemput I, Kesteloot K. Economic implications of non-compliance in health care. *Lancet.* 2002 Jun 22;359(9324):2129-30.

Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. *Archives of Internal Medicine* 150:841-845, 1990.

Iskedjian M, Addis A, Einarson TR. Estimating the cost of hospital admissions due to patient nonadherence in Ontario, Canada. *Pharmacoepid Drug Safety* 1998;7:S92-3

McCarthy R. The price you pay for the drug not taken. *Bus Health.* 1998 Oct;16(10):27-8, 30, 32-3.

Olshaker JS, Barish RA, Naradzay JF, Jerrard DA, Safir E, Campbell L. Prescription noncompliance: contribution to emergency department visits and cost. *J Emerg Med.* 1999 Sep-Oct;17(5):909-12.

Sullivan SD, Kreling DH, Hazlet TK. Noncompliance with medication regimens and subsequent hospitalisations: a literature analysis and cost of hospitalisation estimate. *J Res Pharmaco-Economics* 1990;2:19-33.

11. Respiratory diseases/disorders

Levenson T, Grammer LC, Yarnold PR, Patterson R. Cost-effective management of malignant potentially fatal asthma. *Allergy Asthma Proc.* 1997 Mar-Apr;18(2):73-8.

Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand C. Noncompliance and treatment failure in children with asthma. *J Allergy Clin Immunol* 98: 1051-7, 1996.

12. Urinary & kidney diseases/disorders

Minuth AN. The economic load of the noncompliant patient: must society pay for the shrew? *Artificial Organs* 1992;16:98-101.

Swanson M, Hull D, Bartus SA, Schweizer RT. Economic impact of noncompliance in kidney transplant recipients. *Transplantation Proceedings* 1992;24:2722

13. Women's & Men's health

Hurley JS, Frost EJ, Trinkaus KM, Buatti MC, Emmett KE. Relationship of compliance with hormone replacement therapy to short-term healthcare utilization in a managed care population. *Am J Manag Care.* 1998 Dec;4(12):1691-8.

Review articles

1. Cardiovascular disease/disorders (including smoking, obesity & stroke)

Ambrosioni E. Pharmaco-economic challenges in disease management of hypertension. *J Hypertens Suppl (England)*, Sep 2001, 19(3): S33-40

Hilleman DE, Phillips JO, Mohiuddin SM, et al. A population-based treat-to-target pharmaco-economic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia. *Clinical Therapeutics.* Mar 1999, 21(3): 536-562.

2. Infection

Spiritus E. Antibiotic usage for respiratory tract infections in an era of rising resistance and increased cost pressure. *Am J Manag Care (United States)*, Dec 2000, 6(23 Suppl): S1216-21

Lea AP, Lamb HM. Azithromycin. A pharmaco-economic review of its use as a single-dose regimen in the treatment of uncomplicated urogenital *Chlamydia trachomatis* infections in women. *Pharmacoeconomics (New Zealand)*, Nov 1997, 12(5): 596-611

3. Mental health

Lindstrom E, Bingefors K. Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. *Pharmacoeconomics (New Zealand)*, Aug 2000, 18(2): 106-24

Delgado PL. Approaches to the enhancement of patient adherence to antidepressant medication treatment. *J Clin Psychiatry (United States)*, 2000, 61 Suppl 2: 6-9

Jones MT, Cockrum PC. A critical review of published economic modelling studies in depression. *Pharmacoeconomics*. Jun 2000, 17 (6): 555-583.

4. Other diseases/disorders

Cleemput I, Kesteloot K, De Geest S. A review of the literature on the economics of noncompliance. Room for methodological improvement. *Health Policy (Ireland)*, Jan 2002, 59(1): 65-94

Hughes DA, Bagust A, Haycox A, et al. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. *Health Econ (England)*, Oct 2001, 10(7): 601-15

Hughes DA, Bagust A, Haycox A, et al. Accounting for noncompliance in pharmaco-economic evaluations. *Pharmacoeconomics (New Zealand)*, 2001, 19(12): 1185-97

Peris F, Martinez E, Badia X, Brosa M. Iatrogenic cost factors incorporating mild and moderate adverse events in the economic comparison of aceclofenac and other NSAIDs. *Pharmacoeconomics*. 2001, 19(7): 779-790.

Senst BL, Achusim LE, Genest RP, et al. Practical approach to determining costs and frequency of adverse drug events in a health care network. *Am J Health Syst Pharm*. 2001 JUN 15, 58(12): 1126-1132.

Laederach-Hofmann K, Bunzel B. Noncompliance in organ transplant recipients: a literature review. *Gen Hosp Psychiatry (United States)*, Nov-Dec 2000, 22(6): 412-24

Zyczynski TM, Coyne KS. Hypertension and current issues in compliance and patient

outcomes . *Curr Hypertens Rep (United States)*, Dec 2000, 2(6): 510-4

Feldman JA, De Tullio PL. Medication noncompliance: an issue to consider in the drug selection process. *Hosp Formul (United States)*, Mar 1994, 29(3): 204-11

5. Respiratory disease/disorders

Pinto Pereira LM, Clement Y, Da Silva CK, et al. Understanding and use of inhaler medication by asthmatics in specialty care in Trinidad: A study following development of Caribbean Guidelines for Asthma Management and Prevention. *Chest*. 2002, 121(6): 1833-1840.

Spector-S. Noncompliance with asthma therapy. Are there solutions? *J Asthma*. 2000, 37(5): 381-388.

Books

Compliance in Healthcare and Research. Eds Burke LE, Ockene IS. Armonk (NY): Futura Publishing Co., 2001 (American Heart Association Monograph Series).

Drug Regimen Compliance: Issues in Clinical Trials and Patient Management. Eds: Métry J-M, Meyer UA. Chichester (UK): John Wiley, 1999. (ISBN 0-471-97122-7)

Compliance in Medical Practice and Clinical Trials. Eds: Cramer JA, Spilker B. New York: Raven Press, 1991. (ISBN 0-88167-735-34)

Book chapters

Metry JM. Patient Compliance. In: Fletcher A, Edwards LD, Fox AW, Stonier P, editors. Principles and practice of pharmaceutical medicine. John Wiley and Sons Ltd; 2002:269-79.

Burnier M, Brunner HR. Impact on clinical outcomes. pp 299-309. In: Compliance in Healthcare and Research. Eds Burke LE, Ockene IS. Armonk (NY): Futura Publishing Co., 2001 (American Heart Association Monograph Series).

Urquhart J. Pharmacoeconomic impact of variable compliance. In: Drug Regimen Compliance: Issues in Clinical Trials and Patient Management. Eds: Métry J-M, Meyer UA. Chichester (UK): John Wiley, 1999, pp 119-145. (ISBN 0-471-97122-7)

Abstracts from conference/symposium/workshop

1. Arthritis/osteoporosis/musculoskeletal disorders

2. Cancer

3. Cardiovascular diseases/disorders (including smoking, obesity & stroke)

Benner JS, Ganz DA, Weinstein MC, Neumann PJ, Glynn RJ, Avorn J. Non-compliance with statin therapy: lost clinical benefits and implications for cost-effectiveness [abstract]. *Value Health* 2002;5(3):117.

Benner JS, Ganz DA, Weinstein MC, Neumann PJ, Glynn RJ, Avorn J. Is it cost-effective to improve compliance with lipid-lowering therapy [abstract]? *Value Health* 2002;5(3):126.

Heerey AM, Barry M. Effect on non-adherence to statins on associated cost effectiveness [abstract]. *Value Health* 2002;5(3):176.

Peterson AM, Sanoski CA, McGhan WF. Total direct medical and drug costs of non-adherence to statin therapy within the first year of treatment [abstract]. *Value Health* 2002;5(3):167.

Hughes DA, Bagust A. Impact of non-compliance on the cost-effectiveness of statin therapy [abstract]. *Value Health* 2001;4(6):489-90.

Beck P, Downey W, Butler-Jones D, Lueck L. Pharmaceutical costs of patient non-adherence to lipid-lowering drug therapy [abstract]. *Value Health* 1998;1(1):50.

4. Diabetes/metabolic disorder

5. Eye & skin diseases/disorders

6. Infection

Becker R, Shakur U. The impact of drug compliance on the cost of treating HIV/AIDS in Africa [abstract]. *Value Health* 2001;4(6):439.

Schadlich PK, Brech JG, Frank U, Huppertz E. Patients' compliance and cost-effectiveness of selected oral antibacterials in inpatient treatment of skin and soft tissue infections [abstract]. *Value Health* 2000;3(5):324.

7. *Gastrointestinal diseases/disorders*

Hall JA, Dodd SL, Durkin M, Sloan S. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs [abstract]. *Value Health* 2002;5(3):251.

Goldstein JL, Stewart D, Zabinski RA, Larson LR. The economic implications of decreased patient adherence to co-prescribed diclofenac and misoprostol (CoRx-D&M) relative to a single-tablet formulation of diclofenac/misoprostol (STF-D/M) [abstract]. *Value Health* 1998;1(1):57.

8. *Mental health*

Meddis D, Williams P. Atypical antipsychotics in the treatment of schizophrenia: adverse events, non-compliance and cost [abstract]. *Value Health* 2001;4(6):457.

Simons WR, Bassi R, White R. Antipsychotic compliance evaluation – a population-based, managed-care study of persistence with initially prescribed antipsychotic medication [abstract]. *Value Health* 2001;4(6):456.

9. *Neurological diseases/disorders & pain*

Singer ME. Medical and economic outcomes of noncompliance with dilantin in adult Medicaid epileptics [abstract]. *Value Health* 1998;1(1):47.

10. *Other diseases/disorders*

Iskediian M, Addis A, Einarson T. Estimating the economic burden of hospitalization due to patient nonadherence in Canada [abstract]. *Value Health* 2002;5(6):470-471.

McGuigan KA, Sokol M, Yao J, Haynes J, Qian Q, Boscarino J, Epstein R. The value of compliance: evidence from two patient cohorts [abstract]. *Value Health* 2001;4(2):55.

Hughes D, Bagust A, Haycox A, Walley T. The influence of non-compliance on effectiveness and cost-effectiveness of drug therapies [abstract]. *Value Health* 2000;3(5):373.

Coombs RB, Jensen P, Her MH, Ferguson BS, Jarry JL, Wong JSW, Abrahamssohn RV. Costs of non-compliance and inappropriate use of prescription medication in Canada [web site]. 1997 Available at: http://www.canadapharma.org/Media_Centre/Special_Reports/noncomp97_e.html Last accessed: 05 March 2003.

Schering Report IX. The forgetful patient: the high cost of improper patient compliance [report]. 1987.

The cost of medication waste [website]. May 1997. Available at: <http://www.napra.ca/practice/toolkits/toolkit9/wastecost.pdf> Last accessed: 05 March 2003.

11. Respiratory diseases/disorders

Kutikova L, Bowman L, Morris L. Effectiveness of compliance on health care resource use in asthma patients treated with montelukast vs. inhaled corticosteroids [abstract]. *Value Health* 2001;4(2):81-82.

12. Urinary & kidney diseases/disorders

13. Women's & Men's health

Heaton AH, Flinner A, Martin SL, Emmett KE Buatti MC. Effect of compliance on health and economic outcomes: role of conjugated estrogen on depression and cardiovascular disorders [abstract]. *Value Health* 1998;1(1):29.

Newsletters, editorials, commentaries, special reports

Websites

Others

Contact us

ISPOR Medication Compliance

Joyce A. Cramer
Associate Research Scientist
Department of Psychiatry
Yale University
School of
950 Campbell Ave. (G7E)
West Haven, CT 06516-2770
Tel: 203-937-3894
Fax: 203-937-3468
e-mail: joyce.cramer@yale.edu

**ISPOR Medication Compliance
Bibliography Group**

Jasmanda H. Wu
Associate Director, Outcomes Research
Ortho-McNeil Janssen Scientific Affairs, L.L.C.
1125 Trenton-Harbourton Road
Titusville, NJ 08560-0200
Tel: 609-730-7718
Fax: 609-730-2411
e-mail: jwu2@omjus.jnj.com

Sue Capon
Staff Liaison to
Special Interest Groups
ISPOR
Tel: 609-219-0773, ext. 21
e-mail: scapon@ispor.org